Nicotinamide Improves Aspects of Healthspan, but Not Lifespan, in Mice

Highlights
- Nicotinamide (NAM) supplementation does not extend lifespan in mice
- NAM prevents hepatosteatosis in obese mice while improving glucose metabolism
- NAM reduces oxidative stress and inflammation
- NAM depresses NAM salvage and does not produce a net boost in tissue NAD levels

Authors
Sarah J. Mitchell, Michel Bernier, Miguel A. Aon, ..., Anthony A. Sauve, Joseph A. Baur, Rafael de Cabo

Correspondence
decabora@grc.nia.nih.gov

In Brief
Interventions that increase NAD⁺ bioavailability are of therapeutic interest for the improvement of healthspan and lifespan. Mitchell and Bernier et al. show that chronic treatment with nicotinamide, an NAD⁺ precursor, is associated with health improvements and lower inflammation in the absence of lifespan extension in high-fat-diet-fed mice.
Nicotinamide Improves Aspects of Healthspan, but Not Lifespan, in Mice

Sarah J. Mitchell,¹,₁⁰ Michel Bernier,¹,₁⁰ Miguel A. Aon,¹,² Sonia Cortassa,² Eun Young Kim,¹,³ Evandro F. Fang,⁴ Hector H. Palacios,¹ Ahmed Ali,¹ Ignacio Navas-Enamorado,¹ Andrea Di Francesco,¹ Tamzin A. Kaiser,¹ Tyler B. Waltz,⁴ Ning Zhang,⁵ James L. Ellis,⁶ Peter J. Elliott,⁶ David W. Frederick,⁷ Vilhelm A. Bohr,⁴ Mark S. Schmidt,⁸ Charles Brenner,⁸ David A. Sinclair,¹ Anthony A. Sauve,⁵ Joseph A. Baur,¹ and Rafael de Cabo¹,¹¹,¹²,∗

¹Experimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, MD 21224, USA
²Laboratory of Cardiovascular Science, National Institute on Aging, NIH, Baltimore, MD 21224, USA
³Functional Genomics Research Center, KRIBB, Daejeon 305-806, Republic of Korea
⁴Laboratory of Molecular Gerontology, National Institute on Aging, NIH, Baltimore, MD 21224, USA
⁵Department of Pharmacology, Weill Cornell Medicine, Cornell University, New York, NY 10065, USA
⁶Sirtris, a GSK Company, 200 Technology Square, Cambridge, MA 02139, USA
⁷Department of Physiology, Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania, Philadelphia, PA 19104, USA
⁸Department of Biochemistry, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA
⁹Glenn Labs for the Biological Mechanisms of Aging, Harvard Medical School, Boston, MA 02115, USA
¹⁰These authors contributed equally
¹¹Senior author
¹²Lead Contact
*Correspondence: decabora@grc.nia.nih.gov
https://doi.org/10.1016/j.cmet.2018.02.001

SUMMARY

The role in longevity and healthspan of nicotinamide (NAM), the physiological precursor of NAD⁺, is elusive. Here, we report that chronic NAM supplementation improves healthspan measures in mice without extending lifespan. Untargeted metabolite profiling of the liver and metabolic flux analysis of liver-derived cells revealed NAM-mediated improvement in glucose homeostasis in mice on a high-fat diet (HFD) that was associated with reduced hepatic steatosis and inflammation concomitant with increased glycogen deposition and flux through the pentose phosphate and glycolytic pathways. Targeted NAD metabolome analysis in liver revealed depressed expression of NAM salvage in NAM-treated mice, an effect counteracted by higher expression of de novo NAD biosynthetic enzymes. Although neither hepatic NAD⁺ nor NADP⁺ was boosted by NAM, acetylation of some SIRT1 targets was enhanced by NAM supplementation in a diet- and NAM dose-dependent manner. Collectively, our results show health improvement in NAM-supplemented HFD-fed mice in the absence of survival effects.

INTRODUCTION

Nicotinamide (NAM) is one of three nicotinamide adenine dinucleotide (NAD) precursor vitamins that is largely made available for NAD salvage via degradation of dietary NAD and NADP (Bogan and Brenner, 2008; Trammell et al., 2016a). In yeast, the NAD precursor nicotinamide riboside (NR) (Bieganowski and Brenner, 2004) increases NAD⁺ levels and extends replicative lifespan by ~2-fold (Belenky et al., 2007a). Although NAM can also increase NAD biosynthesis, high-dose NAM acts as a Sir2 inhibitor that reduces lifespan to about half, similar to the effect of deleting Sir2 (Bitterman et al., 2002; Anderson et al., 2002).

In cells, NAM is formed by NAD⁺-consuming enzymes, such as sirtuins, CD38, and poly-ADP-ribose polymerases (PARPs) (Belenky et al., 2007b; Cantó et al., 2015; Verdin, 2015). CD38 is an NADase implicated in the age-related decline in NAD and mitochondrial function impairment via its ability to regulate SIRT3 activity (Camacho-Pereira et al., 2016). As a central metabolic regulator, NAD helps maintain mitochondrial fitness and is essential for tissue health, including nerves and heart (Scheibye-Knudsen et al., 2014; Kaneko et al., 2006; Swerdlow, 1998; Lee et al., 2016). In aging, maintaining NAD⁺ levels keeps nuclear-mitochondrial communication (Gomes et al., 2013). Recent studies indicate that dietary supplementation with NR protects against high-fat-diet (HFD)-induced obesity in mice (Cantó et al., 2012) while improving hepatic function and protecting against diabetic neuropathy (Trammell et al., 2016b). Similarly, nicotinamide mononucleotide (NMN) enhances insulin sensitivity in HFD-fed mice (Yoshino et al., 2011). Moreover, these NAD precursors are effective at extending lifespan and reducing metabolic disease (Khan et al., 2014; Imai, 2010). For example, NR promotes oxidative metabolism by increasing both the NAD⁺/NADH ratio in muscle, liver, and brown adipose tissue and the circulating fatty acid levels (Cantó et al., 2012). Repletion of NAD⁺ stores with NR supplementation improves muscle function and heart defect in a mouse model of muscular dystrophy (Ryu et al., 2016). The similar effects of NMN and NR have been attributed to a common pathway, namely the NR kinase pathway (Ratajczak et al., 2016; Fletcher et al., 2017). In contrast, less is known about the metabolic impact of high NAM dose in rodents, especially with respect to HFD challenge (Yang et al.,
A B C D E F G H I J K L M N O P

legend on next page
2014; Qi et al., 2016). The unanswered questions about NAM are also of interest because the beneficial effects of NR and NMN have been attributed to sirtuin activation in some studies (Yoshino et al., 2011; Cantó et al., 2012; Gomes et al., 2013; Khan et al., 2014), but not others (Trammell et al., 2016b; Zhou et al., 2016).

In the present study, we aimed to characterize the effects of chronic NAM supplementation on the longevity and healthspan characteristics of male C57BL/6J mice fed a synthetic low-fat diet (SD) and the corresponding HFD. Because of the liver’s importance in maintaining metabolic homeostasis, we carried out histological, biochemical, and untargeted metabolomics surveys to provide an unbiased view of the metabolic impact exerted by 62-week NAM supplementation on liver from SD- and HFD-fed mice. Protein target validation combined with metabolic flux analysis enabled the identification of the underlying mechanisms of enhanced glucose disposal and reduced oxidative stress in response to NAM supplementation. Surprisingly, our data showed that NAM depresses NAD salvage and has complex effects on sirtuin expression and activity. NAM appears to have greater beneficial effects in mice subjected to HFD than SD, which might provide important clues about its therapeutic potential in the fight against obesity and associated comorbidities.

RESULTS AND DISCUSSION

To investigate whether NAM improves mouse healthspan and lifespan, we fed 1-year-old male C57BL/6J mice with SD or HFD supplemented with two doses of NAM (0.5 and 1.0 g/kg of diet) for the remainder of their lives (n = 100 mice per experimental group × 6 groups: SD, SDL, SDH, HFD, HDFL, and HFDH). NAM treatment did not affect the mean or maximum lifespan of mice on either diet (Figures 1A and 1B). A gross necropsy examination of all mice that died revealed no histopathological differences between cohorts (Table S1), which confirms that NAM was non-toxic at the given doses. SD-fed mice weighed less than mice on HFD, and NAM supplementation did not alter the average body weight (Figures 1C and 1D) or food consumption (data not shown) between experimental groups.

We assessed several physiological parameters displayed by mice during the experiment (Figure 1E). Body fat percentage was significantly reduced in SDL mice after 25 and 51 weeks of treatment (81 and 107 weeks of age, respectively) (Figures S1A and S1B) with respect to SD. Although NAM-treated mice on SD exhibited unaltered oral glucose tolerance (OGTT; Figure 1F), the SDL mice had significantly lower fasting blood glucose with no effect on circulating insulin levels (Figures S1C and S1D). Mice on HFD supplemented with NAM exhibited a significant decrease in glucose at the OGTT peak (15 min) (Figure 1G), indicating a higher rate of glucose clearance that was associated with a trend toward lower values for the area under the curve (AUC) (Figure 1G, inset; p = 0.08). Insulin levels and homeostatic model assessment of insulin resistance (HOMA-IR) remained unchanged with NAM treatment, although both readouts exhibited a downward trend in HDFL and HFDH mice (Figures S1D and S1E).

In vivo metabolism in mice showed a greater reliance of HFD-fed mice on fatty acid oxidation as their predominant fuel source (respiratory exchange ratio [RER] ~0.75) than SD-fed animals, which consumed a mix of fat and carbohydrates (RER ~0.83) (Figure 1I versus 1H). NAM supplementation provoked predominant carbohydrate fueling in SD-fed mice (RER ~0.9–0.95) (Figure 1I), with a similar trend in HFDH mice (RER ~0.78) (Figure 1I). The flattening of the RER amplitude upon consumption of HFD versus SD was consistent with an earlier report (Kohsaka et al., 2007). Although HFD-fed mice were not as active as their SD counterparts, the HFDH group was associated with greater VO2 and VCO2 values and locomotor activity than HFD controls (Figures S1F and S1G). Note the occurrence of circadian rhythmicity in ambulation (tabulated as activity counts) in all groups of mice. It would appear, therefore, that NAM supplementation partly corrects the diet-associated dampening of the in vivo metabolic/activity pattern.

We then set out to assess healthspan using behavioral and locomotor tests, and the results indicated an improvement in motor coordination and locomotor activity when HFD-fed mice were on chronic NAM supplementation (Figures S1H–S1K).

Histological staining revealed that NAM treatment reduced morphological alterations in the liver that occur as part of normal aging and in response to HFD. Significant improvement in steatosis was observed in HFD-fed mice treated with NAM (Figures 1K and IL) and, in agreement with the heightened glucose metabolism bestowed by NAM supplementation, periodic acid-Schiff staining indicated a marked recovery in hepatic glycogen deposition of non-fasted mice on HFD and NAM (Figures 1M and 1N). Hepatocytic lipid accumulation predisposes to reactive oxygen species excess, endoplasmic reticulum stress, and lipotoxicity.

Figure 1. Nicotinamide (NAM) Treatment Alters Whole-Body Physiology and In Vivo Metabolism without Affecting Maximum Lifespan

(A) Kaplan-Meier survival curves for mice fed a standard diet (SD) or SD supplemented with low dose or high dose of NAM (n = 100/group).
(B) Kaplan-Meier survival curves for mice fed a high-fat diet (HFD) or HFD supplemented with either low dose or high dose of NAM (n = 100/group).
(C and D) Body weight trajectories over the course of the study.
(E) Timetable for the measurement of various outcomes during the treatment protocol.
(F and G) Oral glucose tolerance test. Inset: area under the curve (AUC) (n = 6/group).
(H–J) After 49 weeks of treatment, mice were placed in metabolic cages to measure the respiratory exchange ratio (RER) as detailed in the STAR Methods, n = 6/group.
(K) Hematoxylin and eosin (H&E) staining depicted steatosis as circular white gaps caused when the dehydration process leaches the fat out of fixed liver tissues.
(L) The degree of steatosis was scored and represented as means ± SEM.
(M) Periodic acid-Schiff (PAS) staining for the detection of polysaccharides (e.g., glycogen) in fixed liver tissues.
(N) Semi-quantification of PAS staining and representation as means ± SEM.
(O) Dot blot depicting protein carbonylation levels in the liver of the six experimental groups of mice (n = 4/group).
(P) Quantitative analysis after normalization to protein content.

The data are means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 versus control. (K and M) Scale bar, 100 μm. 100× final magnification. See also Figure S1.
Here, NAM supplementation reduced the formation of carbonylated proteins in liver lysates (Figures 1O and 1P). Together, these results suggested that dietary supplementation with NAM improves glucose metabolism and effectively inhibits liver pathology and oxidative stress while enhancing physical performance of HFD-fed mice.

Liver Metabolite Profiling in NAM-Treated Mice
To better understand the liver’s metabolic response to chronic (62-week) NAM supplementation, we performed untargeted metabolomics in 118-week-old mice subjected to SD or HFD. Both diet and NAM treatment influenced the relative abundance of several metabolites, as demonstrated by significant differences between control and treated groups (Figures 2A and S2A–S2C). Both two-way ANOVA and principal component analyses revealed combined diet-NAM dose-dependent effects, underscoring a higher impact of NAM supplementation on liver metabolism from HFD-fed mice.

Remarkably, NAM supplementation influenced the levels of biochemical markers of glucose metabolism from the metabolomes of SD and HFD groups. Unlike in SD-fed mice, glucose 6-phosphate (G6P) and glucose 1-phosphate (G1P) were less abundant, whereas the tricarboxylic acid (TCA) cycle intermediate citrate increased significantly in HFDL compared with HFD control liver (Figure 2A). The polyol pathway intermediate sorbitol (Brownlee, 2005) exhibited lower levels in mice on HFD and NAM (Figure S2D) concomitantly with a significant decrease in fructose (Figure 2A), suggesting a return path to glycolysis for glyceraldehyde 3-phosphate via fructose 1-phosphate, thus bypassing the potential block of phosphofructokinase-1 by citrate (Hue and Taegtmeyer, 2009) (Figure 2B). However, the flux through the polyol pathway appears to be negligible as suggested by metabolic flux balance analysis (see below).

Together, the data presented suggest that, in HFD-fed mice, NAM supplementation favors liver glucose catabolism concomitantly through glycolysis and glycogen storage.

Figure 2. Impact of NAM on Hepatic Metabolites Profile in Mice Fed SD or HFD
(A) Metabolomics analysis illustrating the relative levels of glucose, fructose, glucose 6-phosphate, glucose 1-phosphate, glycerol 3-phosphate, and citrate. All boxplots represent six mice per group.

(B) Diagram depicting the alteration in glycolytic metabolite concentrations in HFD livers in response to low NAM supplementation. The blockade of phosphofructokinase, liver type (PFKL) by citrate may account for the reduced formation of glyceraldehyde 3-phosphate, which is central in several metabolic pathways. The depletion of glucose 1-phosphate suggests active glycogen synthesis in response to NAM supplementation. Metabolite key: red, accumulated; green, depleted.

The data are means ± SEM. *p < 0.05, **p < 0.01, ****p < 0.0001. See also Figure S2.

(Bechmann et al., 2012). Here, NAM supplementation reduced the formation of carbonylated proteins in liver lysates (Figures 1O and 1P).

Together, these results suggested that dietary supplementation with NAM improves glucose metabolism and effectively inhibits liver pathology and oxidative stress while enhancing physical performance of HFD-fed mice.

Metabolic Flux Analysis and Insulin Responsiveness in HepG2 Cells in the Presence of NAM
Physiological (HOMA-IR and glucose tolerance) and metabolomics readouts suggested that NAM exerts a salutary effect on liver function, apparently mediated by upstream modifications
of key steps in glucose metabolism, especially in mice subjected to HFD.

To investigate NAM’s ability to confer protection against fatty acid-induced metabolic impairment, we examined quantitatively the impact of this compound on glucose and lipid catabolism using a combined experimental-computational approach in liver-derived HepG2 cells. In the absence (control) or the presence of 1 or 2 mM NAM, direct measurements of substrate uptake (glucose, palmitate, and O₂), efflux (pH and lactate), and ATP demand were performed using high-throughput seahorse oxygen consumption (OCR) and extracellular acidification (ECAR) rate measurements (Figures 3A and 3B). Comparatively with controls, ECAR rather than OCR measurements exhibited the more consistent and significant effect of NAM.

Next, we performed flux balance analysis (Savinell and Palsson, 1992; Cortassa et al., 1995) to evaluate steady-state metabolic fluxes under the conditions in which OCR and ECAR were measured. OCR and ECAR fluxes were employed as a reference for an aggregated computational model of central catabolism, which includes carbohydrate (glycolysis, pentose phosphate [PP], and glycogen) and lipid (β-oxidation) degradation pathways in cytoplasmic and mitochondrial compartments.
In the presence of 5 mM glucose (Glc), 200 μM palmitate (Palm, bound to fatty acid-free bovine serum albumin 4:1), and 100 nM insulin, 1 or 2 mM NAM increased ~50% the uptake of glucose (V_Glc) and, only modestly, palmitate (V_Palm,DM) (Figure 3C). Concomitantly, O_2 consumption (V_O2) and lactate efflux (V_Lac) rates augmented ~15% and ~25%, respectively, accompanied by a slight increase in the cellular ATP demand (V_ATPdemand, as-sessed from the flux of protein synthesis as a function of HepG2 cell doubling time under similar conditions). Using our computational model, we could estimate the flux increase through glycolytic (V_glycolysis) and PP (V_PP) pathways as well as the mitochondrial flux distribution via pyruvate dehydrogenase (V_PDH), pyruvate carboxylase (V_PCoA), and citrate synthase (V_Cs) (Figure 3C). Remarkably, low or high NAM concentrations activated the PP pathway flux 8- to 9-fold, accompanied by a relatively much lower but consistent glycolytic flux enhancement. In mitochondria, 2 mM NAM produced a modest increase in V_O2, an effect mediated by flux enhancement through the TCA cycle via acetyl CoA (AccCoA) supplied from β-oxidation of Palm, and glycolytic pyruvate (Pyr) through pyruvate dehydrogenase, complemented by anaplerotic replenishment of oxaloacetate (Oaa) in the TCA cycle through pyruvate carboxylase (Figure 3C). Enzymatically assessed via the levels of fructose in the extracellular medium, the flux through the polyl pathway was negligible (fructose level ~20 pmol at time zero and throughout the assay).

Together, the results obtained show that, in HepG2 cells in the presence of lipids (mimicking HFD), NAM increases glucose catabolism from enhanced glucose uptake and degradation of internal stores of glycogen (more abundant in the liver of HFD-fed mice treated with NAM; see Figures 1M and 1N) processed through glycolytic and PP pathways. In HepG2 cells, ~50% of glucose is oxidized via oxidative phosphorylation and the remainder is excreted as lactate. The remarkable stimulation of the glucose flux redirection through the PP pathway suggests that the favorable effect of NAM on glucose homeostasis might be linked to improved cytoplasmic redox homeostasis via augmented PP pathway-derived NADPH, the main electron donor for cytoplasmic and mitochondrial antioxidant systems (Kembro et al., 2013). Thus, the improvement in glucose homeostasis may be linked to redox balance in HFD-fed mice treated with NAM.

NAM-Mediated Changes in NAD Metabolism

Next, we performed quantitative targeted metabolomics of the NAMPT-NAD-SIRT1 pathway to further assess the impact of NAM on liver redox metabolism. The abundance of nicotinamide phosphoribosyl transferase (NAMPT), which catalyzes NAM conversion into NMN, was markedly lower in HFD compared with SD livers, and NAM treatment caused a significant reduction in NAMPT levels from SD-fed mice (Figure 4A, right panel; Figure S3A). In contrast, the expression of SIRT1 protein was significantly higher in HFD versus SD livers and in response to NAM supplementation irrespective of diet (Figure 4A, left panel; Figure S3A). Figure 4B depicts the strong negative correlation observed between the NAMPT and SIRT1 protein levels (r^2 = 0.761, F = 74.14, p < 0.001). Comparatively, NAMPT levels were sharply reduced in liver and white adipose tissue (WAT), but not in skeletal muscle (Figures S3B and S3C). Likewise, alterations in SIRT1 protein levels were detected in WAT, but not in skeletal muscle, upon NAM supplementation (Figures S3B and S3C).

NAM is also known to alter protein acetylation (Luo et al., 2001) through its concentration-dependent action on sirtuins (Bitterman et al., 2002; Guan et al., 2014), which, in turn, might act as NAM and NAD sensors. While increased NAD bioavailability and greater SIRT1 expression might promote sirtuin activity, increased NAM might also depress sirtuin activity (Bitterman et al., 2002). Immunoblotting of total liver lysates with acetyl-lysin antibody revealed a clear increase in global protein acetylation in response to NAM treatment, especially in HFD-fed mice (Figures S3D and S3E), suggesting overall sirtuin inhibition. Focusing on known SIRT1 downstream targets, we observed a significant NAM-dependent deacetylation of the transcription factors p53 and p65Rel in SD liver, while the acetylated forms of p53 and p65Rel were found elevated in HFDH liver (Figures S3F and S3G). Unlike SIRT1 targets, acetylation of tubulin (SIRT2 target) was significantly reduced in HFDH liver, whereas SOD2 acetylation (SIRT3 target) was unresponsive to NAM (Figures S3F and S3G). These results underscore the complex, dose-dependent effects of NAM on protein acetylation.

Diminished NAMPT levels due to NAM supplementation was surprising, despite previous evidence showing the down-modulation of this enzyme with age and HFD (Yoshino et al., 2011). The involvement in the effect of NAM of the de novo pathway, which converts tryptophan to kynurenine to generate NAD^+ via NAMN and NAD intermediates (Oxenkrug, 2013), was investigated. In HFDL mice liver, we found a significant induction of tryptophan 2,3-dioxygenase (IDO). Immunoblotting of total liver lysates showed a significant increase in IDO, NMNAT1, and NADS levels under NAM (Figures 4C and S4A). Circulating tryptophan was significantly reduced with NAM supplementation (Figure 4D) without altering hepatic tryptophan levels (data not shown), suggesting that NAM leads to activation of the de novo NAD^+ biosynthetic pathway at the expense of NAD salvage.

To assess whether long-term dietary NAM supplementation modifies hepatic NAD^+ metabolism, targeted metabolomics was performed using mass spectrometry analysis as described (Trammell et al., 2016a). The normalized fold change in 13 metabolites from the metabolome of the NAD-related pathways in the six experimental groups is displayed as a heatmap (Figure 4E), and the expression level of different enzymes is indicated (Figure 4F, red and blue dots). We found no significant differences between the NAD metabolome of old mice on SD versus HFD (Figure S4B). Likely, this may be explained by the high carbohydrate content of the SD and the effect of age, which appears to dominate the impact of high fat. Although NAM supplementation did not elevate the steady-state concentration of hepatic NAM, it increased the levels of methylated and oxidized NAM metabolites in a dose-dependent manner. Increased Me-Nam upon NAM supplementation (Figures 4F and S4B) correlated perfectly with higher SIRT1 protein accumulation (Figure 4A), consistent with reports that Me-Nam blocks hepatic SIRT1 proteolysis (Hong et al., 2015; Trammell and Brenner, 2015).

Prior work with younger male C57BL/6J mice on a chow diet, HFD, or HFD with low streptozotocin showed mildly and greatly depressed hepatic NAD^+ and NADP^+, respectively, as a function of obesity and diabetes—these dysregulated NAD^+
metabolomes were largely corrected by NR supplementation at 3 g/kg of diet (Trammell et al., 2016b). In agreement with previous work, we show an NAM-elicited global alteration in the hepatic acetylation profile, which may underlie differential catabolism in HFD- versus SD-fed mice. Acetylation of more than 2,000 non-histone proteins regulates key intermediary metabolic processes involved in glycolysis, the TCA cycle, and fatty acid metabolism (Wang et al., 2010; Zhao et al., 2010; Choudhary et al., 2009; Kim et al., 2006). The dysregulation in acetylation is linked to various human diseases, such as neurodegeneration, cancer, and metabolic disorders (Iyer et al., 2012; Marks, 2010; Kazantsev and Thompson, 2008). Here, we observed an increase in

Figure 4. Impact of NAM Supplementation on Hepatic NAD+ Metabolome and the NAMPT-NAD-SIRT1 Pathway
(A) Scatterplots depicting densitometric analysis after normalization of SIRT1 and NAMPT immunoblots to Ponceau S staining of the membrane, n = 4/group.
(B) Scatterplot displaying the association between NAMPT and SIRT1 protein expression.
(C) Densitometric analysis after normalization of IDO, NMNAT1, and NADS immunoblots to Ponceau S staining of the membrane. Bars represent the average ± SEM (n = 6).
(D) Histograms show the relative tryptophan levels in serum metabolome.
(E) Heatmap illustrates the log2(fold change) values of 13 metabolites from the NAD-related pathway analysis that was evaluated after data normalization with median fold change in each group.
(F) Diagram depicting the effect of dietary supplementation of NAM on the liver NAD+ biosynthetic, salvage, and catabolic pathways. AOX, aldehyde oxidase 1; IDO, indoleamine-pyrrole 2,3-dioxygenase 1; Me-2-py, N-methyl-2-pyridone-5-carboxamide; Me-4-py, N-methyl-4-pyridone-5-carboxamide; MeNAM, methylnicotinamide; NAAD, nicotinic acid adenine dinucleotide; NAD+/NADH, oxidized/reduced nicotinamide adenine dinucleotide; NADP+/NADPH, oxidized/reduced nicotinamide adenine dinucleotide phosphate; NADP+, nicotinamide adenine dinucleotide phosphate synthase; NAM, nicotinamide; NAMN, nicotinic acid mononucleotide; NAMPT, nicotinamide phosphoribosyltransferase; NR, nicotinamidase; NMNAT, nicotinamide/nicotinic acid mononucleotide adenylyltransferase; NNMT, NAM N-methyltransferase; QA, quinolinic acid; SIRT1, sirtuin 1; Trp, tryptophan.

The data are means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figures S3 and S4.
global acetylation in response to a high dose of NAM, especially in HFD-fed mice. The dual action of NAM, acting both as a SIRT1 inhibitor and NAD⁺ precursor, illustrates the complex pharmacological profile of this compound.

We describe beneficial effects of chronic NAM supplementation on the healthspan of HFD-fed mice as revealed by liver metabolism and physical activity measurements. Two of the biochemical effects of NAM, namely increased PP activity and reduced protein carbonylation, are processes that are potentially limited by NADPH. However, in the old mice in this study, NAM depressed NAM salvage and did not produce a net boost in the NAD metabolome. While the increased SIRT1 accumulation might have been anticipated based on Me-Nam-dependent stabilization mechanism (Hong et al., 2015; Trammell and Brenner, 2015), the ability of NAM to depress NAMPT expression was not anticipated. Quantitative metabolomic analysis has made it clear that oral NR boosts hepatic NAD metabolism and sirtuin activity independently of NAMPT (Ratajczak et al., 2016; Fletcher et al., 2017), thereby leading to a wave of hepatic NAM production (Trammell et al., 2016a). Whether this metabolite would undermine or amplify the effect of the boosted NAD metabolome remains in question. Further work is needed to determine whether alteration of the control of NAM catabolism in the liver can promote pro-longevity effects like those elicited by the NAD precursors NR and NMN (de Picciotto et al., 2016; Mills et al., 2016). The data in this study support salutary effects of NAM.

Limitations of the Study
This long-term study on the effect of NAM supplementation was conducted in male mice under two dietary conditions. Our work provides quantifiable evidence that NAM exerts beneficial effects on hepatic glucose metabolism regulation and oxidative stress reduction in the liver of HFD-fed mice, coincident with improved behavioral/physical and metabolic performance without extending longevity. It remains unclear whether similar effects can be observed in other strains of mice and in females. Longitudinal evaluation of phenotypes associated with healthspan would have allowed a better assessment of the impact of NAM on behavioral and motor function tests.

Concluding Remarks
We show for the first time that chronic NAM supplementation can be well tolerated and prevents diet-induced hepatosteatosis while improving glucose metabolism and redox status in livers of HFD-fed mice at 118 weeks of age, independently from food intake, body weight, or body composition. In HFD-fed mice, NAM restored glycogen deposition to the levels observed in the SD-fed group, and in liver-derived HepG2 cells augmented flux through glucose uptake, glycolysis, and PP pathways in the presence of the fatty acid palmitate (to mimic HFD). The remarkable stimulation of the glucose flux redirection through the PP pathway suggests that the favorable effect of NAM on glucose homeostasis might be linked to improved cytoplasmic redox balance via augmented PP pathway-derived NADPH, the main electron donor for cytoplasmic and mitochondrial antioxidant systems. The salutary effects of NAM on reducing oxidative stress and inflammation represent potentially counteracting factors against DNA damage elicited by age and HFD.

STAR★METHODS
Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- CONTACT FOR REAGENT AND RESOURCE SHARING
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Animals and Diets
  - Survival Study
  - Cell Culture
- METHOD DETAILS
  - Body Composition
  - Metabolic Assessment
  - Behavioral Assessment
  - Oral Glucose Tolerance Test (OGTT)
  - Serum Markers and HOMA-IR Calculation
  - Histology
  - Gel Electrophoresis and Western Blotting
  - Metabolomics
  - Determination of Metabolic Fluxes in HepG2 Cells
  - Quantitation of the NAD⁺ Metabolome
- QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and one table and can be found with this article online at https://doi.org/10.1016/j.cmet.2018.02.001.

ACKNOWLEDGMENTS
This research was conducted under a Cooperative Research and Development Agreement (CRADA) between Glaxo Smith-Kline and the National Institute on Aging, NIH (NIA/NIH), and supported in part by the Intramural Research Program of the NIA/NIH. E.Y.K. was supported by a grant from the KRBIB Research Initiative Program (Korean Biomedical Scientist Fellowship Program), Korea Research Institute of Bioscience and Biotechnology, Republic of Korea. D.A.S. was supported by the Paul F. Glenn Foundation for Medical Research, NIH/NIA MERIT award R01 AG028730, and a gift from Edward Schullik. Special thanks to the members of the Translational Gerontology Branch and the Comparative Medicine Section of the NIA. We acknowledge Dawn Phillips, Dawn Nines, and Justice Lucas for animal care; Olga Carlson for insulin measurements; Elin Lehmann and Paul Bastian for their expertise in microarray analysis; and Theresa Ward, Robin K. Minor, Michael A. Petri, Irene Alfaras, and Joseph H. Garcia for their contributions to this work.

AUTHOR CONTRIBUTIONS

DECLARATION OF INTERESTS
J.L.E. is a former employee and a stockholder in GlaxoSmithKline (GSK), and a current SAB member of Metro Biotech. P.J.E. is a former employee of Sirtris, a...
GSK company, V.A.B. has a CRADA with ChromaDex. C.B. owns stock in ChromaDex and serves as a consultant to ChromaDex and Cytokinetics. A.A.S. receives royalties on commercial sales of nicotinamide riboside from ChromaDex. A.A.S. is also a consultant and co-founder of Metro MidAtlantic Biotech LLC. D.A.S. is a consultant, equity owner, and inventor on patents licensed to Life Biosciences, Metro International Biotech, Jumpstart Fertility, Liberty Biosecurity, Ovascience, and GSK. The remaining authors declare no competing interests.

Received: January 31, 2017
Revised: September 19, 2017
Accepted: February 2, 2018
Published: March 6, 2018

SUPPORTING CITATIONS

The following reference appears in the Supplemental Information: Aitken et al., 2010.

REFERENCES


administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 24, 1–12.
STAR METHODS

KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibodies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rabbit anti-acetyl-lysine</td>
<td>ImmunoChem Pharmaceuticals</td>
<td>cat#ICP0380</td>
</tr>
<tr>
<td>mouse anti-tubulin</td>
<td>Santa Cruz Biotechnology</td>
<td>cat#sc-5286; RRID: AB_628411</td>
</tr>
<tr>
<td>rabbit anti-acetylated tubulin</td>
<td>Cell Signaling Technology</td>
<td>cat#5335S; RRID: AB_10544694</td>
</tr>
<tr>
<td>mouse anti-SIRT1</td>
<td>Sigma-Aldrich</td>
<td>cat#S5196; RRID: AB_532284</td>
</tr>
<tr>
<td>mouse anti-p53</td>
<td>Cell Signaling Technology</td>
<td>cat#2524; RRID: AB_331743</td>
</tr>
<tr>
<td>rabbit anti-acetylated p53</td>
<td>Cell Signaling Technology</td>
<td>cat# 2570S; RRID: AB_823591</td>
</tr>
<tr>
<td>rabbit anti-p65</td>
<td>Abcam</td>
<td>cat#ab32536; RRID: AB_776751</td>
</tr>
<tr>
<td>rabbit anti-acetylated p65</td>
<td>Abcam</td>
<td>cat#ab19870; RRID: AB_776753</td>
</tr>
<tr>
<td>rabbit anti-SOD2</td>
<td>Abcam</td>
<td>cat#ab13533; RRID: AB_300434</td>
</tr>
<tr>
<td>rabbit anti-acetylated SOD2</td>
<td>Abcam</td>
<td>cat#ab137037</td>
</tr>
<tr>
<td>rabbit anti-NAMPT</td>
<td>Bethyl Laboratories</td>
<td>cat#A300-372A-M</td>
</tr>
<tr>
<td>goat anti-IDO</td>
<td>Abcam</td>
<td>cat#ab134197</td>
</tr>
<tr>
<td>rabbit anti-NMNAT-1</td>
<td>Santa Cruz</td>
<td>cat#sc-98249; RRID: AB_2153131</td>
</tr>
<tr>
<td>rabbit anti-NADS</td>
<td>Abcam</td>
<td>cat#ab139561</td>
</tr>
<tr>
<td>Critical Commercial Assays</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse insulin ELISA</td>
<td>Crystal Chem</td>
<td>90080</td>
</tr>
<tr>
<td>OxiSelect Protein Carbonyl Immunoblot kit</td>
<td>Cell Biolabs</td>
<td>STA-308</td>
</tr>
<tr>
<td>Experimental Models: Cell Lines</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human: HepG2</td>
<td>ATCC</td>
<td>HB-8065</td>
</tr>
<tr>
<td>Experimental Models: Organisms/Strains</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse: C57BL/6J</td>
<td>The Jackson Laboratory</td>
<td>JAX 000664</td>
</tr>
<tr>
<td>Software and Algorithms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prism 6.0</td>
<td>GraphPad</td>
<td><a href="http://www.graphpad.com/scientific-software/prism">http://www.graphpad.com/scientific-software/prism</a>; RRID: SCR_015807</td>
</tr>
<tr>
<td>Excel 2010</td>
<td>Microsoft</td>
<td>N/A</td>
</tr>
</tbody>
</table>

CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Rafael de Cabo (decabora@mail.nih.gov).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Animals and Diets
Male C57BL/6J mice were purchased from the Jackson Laboratory (Bar Harbor, ME) (stock number: 000664) and housed at the Gerontology Research Center and Biomedical Research Center (Baltimore, MD). Mice were housed in cages of four with ad libitum access to diet and tap water. Mice were electronically tagged for identification (Biomedic Data System, Maywood, NJ), and body-weight and food intake were monitored every two weeks from the start of the study for the duration of their lifespan. Animal rooms were maintained at 20–22°C with 30–70% relative humidity and a 12-hour light/dark cycle. Diets were started at 56 weeks of age after randomization into six groups of 100 mice per group. Mice were fed one of six study diets: (a) standard AIN-93G diet (SD; carbohydrate:protein:fat ratio of 64:19:17 percent of kcal), (b) SD + 0.5g nicotinamide (NAM)/kg chow (SDL), (c) SD+1.0g NAM/kg chow
(SDH), (d) a high fat diet (HFD: carbohydrate:protein:fat ratio of 16:23:61 percent of kcal), (e) HFD+0.5g NAM/kg chow (HFDL) or (f) HFD + 1.0g NAM/kg chow (HFDH). These levels of NAM corresponded to 37.5 (SHD, HDFL) and 75 (SDH, HFDH) mg/g BW/day. Study diets were purchased from Dyets, (Bethlehem, PA). NAM was obtained from Sigma-Aldrich (St Louis, MO). No inclusion or exclusion criteria were used. All animal protocols were approved by the Animal Care and Use Committee (352-TGB-2013, 352-TGB-2016) of the National Institute on Aging.

**Survival Study**

Animals were inspected twice daily for health issues and deaths were recorded for each animal. Moribund animals were euthanized and every animal found dead or euthanized was necropsied. Criteria for euthanasia were based on an independent assessment by a veterinarian according to the AAALAC guidelines. Only cases where the condition of the animal was considered incompatible with continued survival are represented as deaths in the curves. Animals removed at sacrifice or euthanized due to reasons unrelated to incompatible survival were considered as censored deaths and these included animals that died due to flooded cages or sacrificed for tissue collection. For euthanasia and subsequent tissue collection, mice were on their normal feeding cycle (study diet ad libitum) and not fasted.

**Cell Culture**

The HepG2 human hepatocellular carcinoma cell line (ATCC, Manassas, VA) was derived from the liver tissue of a 15-year-old Caucasian male. ATCC uses short tandem repeat (STR) analysis to authenticate cell lines. Upon receipt from ATCC, HepG2 cells were expanded for a few passages to generate new frozen stocks. Cells were resuscitated as needed and used for no more than 10-12 passages or no more than 8-10 weeks after resuscitation. Cells were maintained in MEM supplemented with 2 mM Glutamax, 1% sodium pyruvate, 100 units/ml penicillin, 100 μg/ml streptomycin, and 10% fetal bovine serum (HyClone, Logan, UT). Cells were maintained in culture at 37°C in a humidified incubator with 5% CO2 and the medium was replaced every 2-3 days. Details about metabolic flux analysis in these cells can be found in a sub-section below.

**METHOD DETAILS**

**Body Composition**

Measurements of lean, fat and fluid mass in live mice were acquired by nuclear magnetic resonance (NMR) using the Minispec LF90 (Bruker Optics, Billerica, MA). Measurements were made in 81- and 107-week old mice, which correspond to 25 and 51 weeks on diet, respectively.

**Metabolic Assessment**

Mouse metabolic rate was assessed by indirect calorimetry in open-circuit oxymax chambers using the Comprehensive Lab Animal Monitoring System (CLAMS; Columbus Instruments, Columbus, OH) as previously described (Minor et al., 2011). Mice (105-week old, 49 weeks on diet) were housed singly with water and food available ad libitum and maintained at ~24°C under a 12:12-h light-dark cycle (light period 0600-1800). All mice were acclimatized to monitoring cages for 3-6 h before recording began. Sample air was passed through an oxygen (O2) sensor for determination of O2 content. O2 consumption was determined by measuring oxygen concentration in air entering the chamber compared with air leaving the chamber. The sensor was calibrated against a standard gas mix containing defined quantities of O2, carbon dioxide (CO2), and nitrogen (N2). Constant airflow (0.6 L/min) was drawn through the chamber and monitored by a mass-sensitive flow meter. The concentrations of O2 and CO2 were monitored at the inlet and outlet of the sealed chambers to calculate oxygen consumption. Each chamber was measured for 30 s at 30-min intervals and data were recorded for 60 h total. Movement (both horizontal and vertical) was also monitored. The system has beams 0.5-inch apart on the horizontal plane providing a high-resolution grid covering the XY-planes and the software provides counts of beam breaks by the mouse in 30-s epochs.

**Behavioral Assessment**

Mice were tested at the same time of day over a five-day period. On the testing day, mice were brought to the testing room and allowed to acclimatize for 2-3 h. Rotarod. Mice were given a habituation trial on day 1 where they were placed on the rotarod at a constant speed (4 r.p.m.) and had to remain on the rotarod for 5 min. On the testing day, mice were placed on the accelerating rotarod (4–40 r.p.m. over 5 min) and given three trials (30-min rest period in between trials). Results shown are the average of three trials per mouse. The maximum trial length was 5 min. Cage top. A metal cage top was turned upside down, with its sides covered in duct tape, and the experimenter placed the mouse on top of cage top. The cage top was then turned until the mouse was hanging from the cage top with all four limbs grasping the bars. Each mouse was given three trials (maximum latency of 60 s) with a 30-min rest period in between trials. Data is shown as the average of three tests. Open field. Mice were placed individually into the center of a plexiglass square measuring 23in x 23in. The open field was evenly illuminated and exploratory behavior was measured for 300 s using AnyMaze software (Stoelting, Wood dale, IL). The apparatus was cleaned with 70% alcohol before testing the next mouse. This was repeated over a five-day period and data are presented as the average over this period. Mice were 115-week old, 59 weeks on diet.
**Oral Glucose Tolerance Test (OGTT)**
Following an overnight fast, mice (97-week old, 41 weeks on diet, n=6 per group) received a 30% glucose solution (1.5 g/kg glucose by gavage). Blood glucose was measured using an Breeze2 glucose meter (Bayer, Mishawaka, IN) at 0, 15, 30, 60 and 120 min following gavage.

**Serum Markers and HOMA-IR Calculation**
Fasting blood glucose (16h fast) was determined using an Breeze2 glucose meter and fasting serum insulin (16h fast) was measured using an enzyme-linked immunosorbent assay (Crystal Chem, Downers Grove, IL) according to the manufacturer’s instructions. Insulin resistance was calculated from fasted glucose and insulin values using the HOMA2 Calculator software available from the Oxford Centre for Diabetes, Endocrinology and Metabolism, Diabetes Trials Unit website (http://www.dtu.ox.ac.uk/).

**Histology**
Fresh frozen liver sections from non-fasted mice were cut on a cryostat (Leica Microsystems, Wetzlar, Germany) at 10 μm thickness and mounted on glass coverslips. H & E staining was performed to evaluate liver architecture while Periodic-Acid Schiff (PAS) reagent was used to stain for glycogen according to well-established protocols. Scoring of the glycogen content (PAS staining) was performed by 3 independent observers blinded to the treatment groups. This was performed on at least 10 fields/animal (minimum 60 images/treatment group) with the data representing the average of three scores. PAS staining was determined by assigning an equally weighted arbitrary score of 0 (no visible glycogen staining) to 3 (normal glycogen deposition) for each image and averaging the score per treatment group.

**Gel Electrophoresis and Western Blotting**
Separation of mouse liver extracts was carried out according to standard procedures. N=6 mice per group, 118-week old, 62 weeks on dietary intervention. Tissues were lysed either in radioimmunoprecipitation buffer (RIPA) or urea lysis buffer supplemented with ethylenediaminetetraacetic acid and ethylene glycol tetraacetic acid (Boston BioProducts, Ashland, MA) along with KDAC inhibitors [10 μM trichostatin A, 10 mM NAM, and 50 mM butyric acid, all from Sigma-Aldrich], and protease and phosphatase inhibitors (Roche, Indianapolis, IN). Following homogenization with a polytron homogenizer, samples were centrifuged (14,000 rpm, 30 min at 4°C) and protein concentration in the clarified lysates was then quantified using the Bradford assay method (Bio-Rad). Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis under reducing conditions and then transferred to nitrocellulose membranes. Western blots were performed according to standard methods unless otherwise specified. Membranes were blocked for 1 h in 5% milk, and then incubated overnight at 4°C with the antibody of interest, followed by incubation with a secondary antibody. Antibodies used were anti-acetyl-lysine antibody (cat#: ICP0380; ImmunoChem Pharmaceuticals, Burnaby, BC, Canada); tubulin (cat#: sc-5286; Santa Cruz Biotechnology, Santa Cruz, CA); acetylated tubulin (cat#: cs-5335; Cell Signaling Technology (CST), Denver, MA); SIRT1 (cat#: s5196, Sigma-Aldrich; and cat#: ab110304, Abcam, Cambridge, MA); p53 (cat#: cs-2524; CST); acetylated p53 (cat#: cs-2570; CST); p65 (cat#: ab32536; Abcam); acetylated p65 (cat#: ab19870; Abcam); SOD2 (cat#: ab13533; Abcam); acetylated SOD2 (cat#: ab137037; Abcam); NAMPT (cat#: A300-372A-M, Bethyl Laboratories, Montgomery, TX); IDO (cat#: ab134197, Abcam); NMNAT-1 (cat# sc98249, Santa Cruz); NADS (cat# ab139561, Abcam). The visualization of immunoreactive bands was performed using the ECL Plus Western blotting detection system (GE Healthcare, Pascataway, NJ). The quantification was performed by volume densitometry using ImageJ software (National Institutes of Health, Bethesda, MD) and normalization to Ponceau S staining (Sigma-Aldrich).

**Metabolomics**
Metabolomic analysis was performed by the West Coast Metabolomics Center at UC Davis (Davis, CA) in livers and serum of non-fasted animals as previously described (Mitchell et al., 2016). In brief, liver tissue (4 mg) was homogenized in extraction solution (acetonitrile:isopropanol:water, 3:3:2), then vortexed for 45 s and incubated for 5 min at 4°C. Following centrifugation at 14,000 rcf for 2 min, two aliquots of the supernatant (500 μl each aliquot) were made for analysis and one for backup. One aliquot was dried via evaporation overnight in the Labconco Centrivap cold trap concentrator (Labconco, Kansas City, MO). The dried aliquot was then resuspended with 500 μl 50% acetonitrile (degassed) and centrifuged at 14,000 rcf for 2 min. The supernatant was transferred to a clean Eppendorf tube and evaporated again to dryness. Internal standards (C8-C30 fatty acid methyl esters) were then added and the sample was derivatized by methoxyamine.HCl in pyridine and subsequently by N-methyl-N-trimethylsilyltrifluoro acetemide for trimethylsilylation of acidic protons. Data were acquired using the method as described (Fiehn et al., 2008), which is briefly summarized in Mitchell et al. (2016). Data are presented as a ratio of the metabolite to the total metabolites returned. N=6 mice per group, 118-week old, 62 weeks on dietary intervention.

**Determination of Metabolic Fluxes in HepG2 Cells**
HepG2 cells were seeded at 1.6 x 10^4 cells on a 24-multiwell Seahorse plate in low-glucose DMEM supplemented with 5% FBS, 100 nM insulin, and in presence of NAM (0, 1 or 2 mM) overnight. Cells were washed twice and then maintained in Seahorse glucose-free DMEM in the absence of FBS, insulin, and NAM for 45 min in the temperature controlled instrument set at 37°C before the addition of glucose (1 mM final concentration), insulin (100 nM), and NAM (0, 1 or 2 mM) for 1 h, as indicated. After three baseline measurements of the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) on the Seahorse XF24 instrument
(North Billerica, MA), aliquots of stock solutions containing glucose (4 mM final concentration + 1 mM already with cells = 5 mM),
palmitate (200 μM in a 4:1 ratio with fatty acid-free BSA), or the combination glucose + palmitate were added. For the next hour,
the metabolic phenotype of these cells —mitochondrial respiration and glycolysis— was measured through the relative utilization
of the two substrates. Preliminary experiments were carried out to demonstrate the linearity of the OCR and ECAR response as a
function of the cell number and the expected behavior in the presence of the mitochondrial inhibitors, oligomycin (10 μM), FCCP
(1.23 μM), and antimycin A/rotenone (10 μM each) (Reily et al., 2013).

Metabolic flux balance analysis (Savinell and Palsson, 1992; Cortassa et al., 1995) was used to estimate the fluxes through the
network of metabolic pathways involved in the degradation of glucose and palmitate (Palm) consumption. The algebraic calculation
of metabolic fluxes requires the input of several fluxes: glucose uptake (VGLc), lactate efflux (VLact), oxygen consumption (VO2), Palm
oxidation (VPalm_Ox) and ATP demand (VATPdemand, estimated from the rate of protein synthesis during growth under similar conditions
to those used in the Seahorse experiments under the assumption that protein synthesis is ~50% of the total ATP demand). Those five
fluxes were used as a reference in the algebraic solution corresponding to the estimated fluxes through the metabolic network
considered. These estimated fluxes include VPep, which stands for the glucose flux through the pentose phosphate (PP) pathway
that in the presence of NAM is derived from degradation of glycogen stores, glycolysis (VGlycolysis), citrate synthase (VCIT), pyruvate
dehydrogenase (VPDH), and pyruvate carboxylase (VPCb).

**Quantitation of the NAD⁺ Metabolome**
Sample preparation and targeted quantitative metabolomics were carried out for complete analysis of the NAD⁺ metabolome as
described (Trammell et al., 2016a). Heatmaps of the average intensity of metabolites in each group and Log2(fold change) calculation
were performed using Microsoft Excel (Microsoft, Redmond, WA). Mice were 118-week old, and 62 weeks on dietary intervention.
SD, n=6; SDL, n=5; SDH, n=5; HFD, n=6; HFDL, n=6; HFDH, n=5.

**QUANTIFICATION AND STATISTICAL ANALYSIS**
Mortality during the survival study was assessed using the log rank test to compare the differences in Kaplan-Meier survival curves.
Maximal lifespan was defined as the 10th percentile of mice still alive. Two-way analysis of variance (ANOVA) was performed for
mRNA, protein expression, or metabolomics analysis, and the two independent factors were diet (SD or HFD) and NAM concentra-
tions (none, low and high). Data are expressed as means ± standard error of the mean (SEM), with p value of ≤ 0.05 considered sta-
tistically significant. The statistical parameters (n, mean, SEM) can be found within the figure legends. No statistical method was used
to determine whether the data met assumptions of the statistical approach. Analyses were performed using Graph Pad Prism 6.0
(San Diego, CA), Excel 2010 (Microsoft, Redmond, WA), and SigmaStat 3.0 (Aspire Software International, Ashburn, VA).